SEELOS THERAPEUTICS INC - SEEL STOCK NEWS

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced participation in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021. Chairman and CEO Raj Mehra, Ph.D. will hold one-on-one meetings via conference calls. The company focuses on developing therapies for central nervous system disorders and rare diseases, working on late-stage clinical assets targeting serious conditions like Acute Suicidal Ideation, amyotrophic lateral sclerosis, and more. For further details, visit Seelos Therapeutics.

Seelos Therapeutics (Nasdaq: SEEL) announced the grant of a stock option for 50,000 shares to a new employee, under its 2019 Inducement Plan, compliant with Nasdaq Rule 5635(c)(4). The exercise price is set at $0.97, the closing share price on December 1, 2020. Vesting is structured over four years, with one-fourth vesting annually and the remainder monthly, contingent on continuous employment. This indicates the company's commitment to attracting talent in the competitive biopharmaceutical sector.

Seelos Therapeutics has received Orphan Drug Designation (ODD) from the FDA for SLS-005, a treatment for amyotrophic lateral sclerosis (ALS). The drug is part of a Phase IIb/III clinical trial with plans to enroll 160 patients, assessing its impact on ALSFRS-R scores and other key metrics after 24 weeks. SLS-005 also holds ODD for conditions like Sanfilippo syndrome and spinsocerebellar ataxia type 3. The designation provides multiple development incentives, including tax credits for clinical testing.

Seelos Therapeutics (Nasdaq: SEEL) will participate in the 3rd International Conference on Sanfilippo Syndrome on Nov. 13, 2020, at 2:30 PM CET. The session, led by CEO Raj Mehra, will focus on Trehalose (SLS-005), a potential treatment for MPS III. The conference aims to enhance collaboration between researchers, biotechnology firms, and families affected by rare diseases. The Sanfilippo Foundation Switzerland, which supports research into this syndrome, has raised over 8 million Swiss Francs for ten innovative research programs to date.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced the issuance of U.S. patent number 10815271 for SLS-007, a gene therapy targeting α-synuclein aggregates linked to Parkinson's disease. The patent covers the composition of matter and methods for reducing α-synuclein aggregation. The company is conducting an in vivo preclinical study to evaluate the pharmacokinetics and pharmacodynamics of SLS-007, with preliminary results expected in Q1 2021. CEO Raj Mehra emphasized the potential of SLS-007 to slow Parkinson's progression through a gene therapy approach.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in two investor conferences in November 2020. The events include the Jefferies Virtual Global Healthcare Conference from November 17-19 and the Benchmark Virtual Discovery One on One Investor Conference on November 18. Senior management, including Chairman and CEO Raj Mehra and Head of Research and Development Dr. Tim Whitaker, will host one-on-one meetings via conference calls. Seelos focuses on developing therapies for central nervous system disorders and rare diseases.

Seelos Therapeutics (Nasdaq: SEEL) has signed a Sponsored Research Agreement with Duke University to study SLS-004, an innovative gene therapy for Parkinson's Disease (PD). The collaboration aims to use a mouse model to initiate proof-of-concept tests for the LV-dCas9-DNMT3A virus in preventing or delaying PD. This research builds on previous work focusing on a vector designed to modify α-synuclein protein expression. SLS-004 employs a novel epigenome-editing technique to effectively downregulate the SNCA gene, demonstrating potential as a new therapeutic strategy for PD.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced the issuance of a new patent (Japanese patent number 6722453) covering SLS-002, aimed at treating anxiety from phobic disorders such as Specific Phobia and Social Phobia. Additionally, the company received a Notice of Allowance for another patent application (Japanese patent number 2018-124196) that covers SLS-002's use in preventing anxiety before medical or dental procedures. These developments strengthen Seelos's intellectual property portfolio in the CNS disorder therapeutic area.

Seelos Therapeutics (Nasdaq: SEEL) announced a Notice of Allowance from the USPTO for its patent application on trehalose (SLS-005). This patent covers methods to treat various neurodegenerative diseases, including spinocerebellar ataxia and frontotemporal dementia. Trehalose is known for its ability to cross the blood-brain barrier and activate autophagy, which may help reduce protein aggregation in cells. The allowance of this patent is a significant step for Seelos in its development of therapies targeting central nervous system disorders.